PD-L1 Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about PD-L1 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery

Mucosal MelanomaPD-L1 Positive
The First Hospital of Jilin University220 enrolled1 locationNCT07400302
Recruiting

Predicting Clinical Efficacy of Immunotherapy Using Pre-treatment andContinuousMonitoring of PD-L1 TPS/CPS on CTCs, and Immunity Exhaustion Scores

ImmunotherapyCirculating Tumor Cells (CTCs)PD-L1 Expression+1 more
Chang Gung Memorial Hospital150 enrolled1 locationNCT07396259
Recruiting
Phase 1Phase 2

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Pancreatic CancerPD-1 InhibitorPD-L1+2 more
Zhejiang Provincial People's Hospital10 enrolled1 locationNCT07312422
Recruiting
Phase 3

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.400 enrolled2 locationsNCT07111832
Recruiting

TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%

NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled19 locationsNCT07279402
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Not Applicable

Biomarkers in Immunotherapy of Melanoma

Metastatic MelanomaImmune Checkpoints InhibitorsGastrointestinal Microbiome (Bacterial and Viral)+1 more
Institute of Oncology Ljubljana150 enrolled1 locationNCT05878977